DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 2,008 filers reported holding DANAHER CORPORATION in Q1 2022. The put-call ratio across all filers is 1.38 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $18,697,945 | +2.5% | 75,365 | -0.8% | 1.73% | +3.5% |
| Q2 2023 | $18,242,507 | -11.6% | 76,010 | -7.2% | 1.67% | -1.1% |
| Q1 2023 | $20,636,111 | -3.8% | 81,876 | +1.3% | 1.69% | -5.2% |
| Q4 2022 | $21,461,925 | -99.9% | 80,860 | -0.4% | 1.78% | -4.3% |
| Q3 2022 | $20,973,959,000 | +10.2% | 81,203 | +8.2% | 1.86% | +20.1% |
| Q2 2022 | $19,031,253,000 | -15.8% | 75,068 | -2.6% | 1.55% | +2.8% |
| Q1 2022 | $22,596,383,000 | -12.6% | 77,034 | -2.0% | 1.51% | -4.9% |
| Q4 2021 | $25,859,857,000 | +8.2% | 78,599 | +0.1% | 1.59% | -0.4% |
| Q3 2021 | $23,899,758,000 | +15.1% | 78,504 | +1.4% | 1.59% | +15.2% |
| Q2 2021 | $20,769,454,000 | +20.4% | 77,394 | +1.0% | 1.38% | +6.5% |
| Q1 2021 | $17,253,732,000 | +2.0% | 76,656 | +0.7% | 1.30% | -5.7% |
| Q4 2020 | $16,911,962,000 | +1.7% | 76,132 | -1.4% | 1.38% | -19.0% |
| Q3 2020 | $16,627,998,000 | +18.7% | 77,221 | -2.5% | 1.70% | +8.2% |
| Q2 2020 | $14,006,174,000 | +27.1% | 79,207 | -0.5% | 1.57% | +8.5% |
| Q1 2020 | $11,022,972,000 | -8.5% | 79,640 | +1.5% | 1.45% | +13.8% |
| Q4 2019 | $12,041,887,000 | +17.3% | 78,459 | +3.3% | 1.27% | +13.2% |
| Q3 2019 | $10,270,178,000 | -6.7% | 75,946 | -1.4% | 1.12% | -8.8% |
| Q2 2019 | $11,011,986,000 | +7.4% | 77,050 | -0.8% | 1.23% | +3.4% |
| Q1 2019 | $10,256,766,000 | +28.2% | 77,691 | +0.1% | 1.19% | +15.5% |
| Q4 2018 | $8,001,906,000 | -3.6% | 77,598 | +1.5% | 1.03% | +18.8% |
| Q3 2018 | $8,304,015,000 | +16.5% | 76,422 | +5.8% | 0.87% | +9.2% |
| Q2 2018 | $7,130,321,000 | -1.0% | 72,257 | -1.8% | 0.80% | -0.5% |
| Q1 2018 | $7,205,980,000 | +15.7% | 73,598 | +9.7% | 0.80% | +19.6% |
| Q4 2017 | $6,227,665,000 | +7.3% | 67,094 | -0.8% | 0.67% | +1.4% |
| Q3 2017 | $5,801,645,000 | -3.9% | 67,634 | -5.5% | 0.66% | -4.8% |
| Q2 2017 | $6,036,754,000 | -0.3% | 71,534 | +1.0% | 0.69% | -2.1% |
| Q1 2017 | $6,055,353,000 | +6.6% | 70,798 | -3.0% | 0.71% | +2.6% |
| Q4 2016 | $5,682,554,000 | -4.1% | 73,003 | -3.5% | 0.69% | -4.6% |
| Q3 2016 | $5,927,617,000 | -22.4% | 75,617 | +0.0% | 0.72% | -24.1% |
| Q2 2016 | $7,634,893,000 | +2.5% | 75,593 | -3.8% | 0.95% | +2.1% |
| Q1 2016 | $7,450,874,000 | +2.3% | 78,546 | +0.1% | 0.93% | -1.9% |
| Q4 2015 | $7,286,436,000 | +23.2% | 78,450 | +13.0% | 0.95% | +16.6% |
| Q3 2015 | $5,913,915,000 | +2.8% | 69,404 | +3.3% | 0.81% | +11.8% |
| Q2 2015 | $5,751,648,000 | +18.7% | 67,200 | +17.7% | 0.73% | +18.6% |
| Q1 2015 | $4,847,366,000 | -1.1% | 57,095 | -0.2% | 0.61% | +1.8% |
| Q4 2014 | $4,902,526,000 | +11.5% | 57,199 | -1.2% | 0.60% | +8.6% |
| Q3 2014 | $4,396,887,000 | -1.8% | 57,869 | +1.8% | 0.56% | +0.5% |
| Q2 2014 | $4,475,249,000 | +5.7% | 56,843 | +0.7% | 0.55% | +1.5% |
| Q1 2014 | $4,231,950,000 | -39.4% | 56,426 | -37.6% | 0.54% | -40.6% |
| Q4 2013 | $6,980,887,000 | +10.7% | 90,426 | -0.6% | 0.92% | +1.3% |
| Q3 2013 | $6,304,446,000 | +8.6% | 90,947 | -0.8% | 0.90% | +5.1% |
| Q2 2013 | $5,802,711,000 | – | 91,670 | – | 0.86% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |